217 related articles for article (PubMed ID: 21411814)
1. Visualization of CD44 and CD133 in normal pancreas and pancreatic ductal adenocarcinomas: non-overlapping membrane expression in cell populations positive for both markers.
Immervoll H; Hoem D; Steffensen OJ; Miletic H; Molven A
J Histochem Cytochem; 2011 Apr; 59(4):441-55. PubMed ID: 21411814
[TBL] [Abstract][Full Text] [Related]
2. Expression of the "stem cell marker" CD133 in pancreas and pancreatic ductal adenocarcinomas.
Immervoll H; Hoem D; Sakariassen PØ; Steffensen OJ; Molven A
BMC Cancer; 2008 Feb; 8():48. PubMed ID: 18261235
[TBL] [Abstract][Full Text] [Related]
3. Coexpression of CD44-positive/CD133-positive cancer stem cells and CD204-positive tumor-associated macrophages is a predictor of survival in pancreatic ductal adenocarcinoma.
Hou YC; Chao YJ; Tung HL; Wang HC; Shan YS
Cancer; 2014 Sep; 120(17):2766-77. PubMed ID: 24839953
[TBL] [Abstract][Full Text] [Related]
4. Expression of cancer stem cell markers in pancreatic intraepithelial neoplasias and pancreatic ductal adenocarcinomas.
Kure S; Matsuda Y; Hagio M; Ueda J; Naito Z; Ishiwata T
Int J Oncol; 2012 Oct; 41(4):1314-24. PubMed ID: 22824809
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of cancer stem cell marker CD133 expression in pancreatic ductal adenocarcinoma (PDAC): a systematic review and meta-analysis.
Li X; Zhao H; Gu J; Zheng L
Int J Clin Exp Pathol; 2015; 8(10):12084-92. PubMed ID: 26722393
[TBL] [Abstract][Full Text] [Related]
6. CD133 expression pattern distinguishes intraductal papillary mucinous neoplasms from ductal adenocarcinomas of the pancreas.
Shimizu K; Itoh T; Shimizu M; Ku Y; Hori Y
Pancreas; 2009 Nov; 38(8):e207-14. PubMed ID: 19786935
[TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of tumorbiology and CD133 positivity in primary and recurrent pancreatic ductal adenocarcinoma.
Welsch T; Keleg S; Bergmann F; Degrate L; Bauer S; Schmidt J
Clin Exp Metastasis; 2009; 26(7):701-11. PubMed ID: 19488831
[TBL] [Abstract][Full Text] [Related]
8. Expression of the stem cell markers CD133 and nestin in pancreatic ductal adenocarcinoma and clinical relevance.
Kim HS; Yoo SY; Kim KT; Park JT; Kim HJ; Kim JC
Int J Clin Exp Pathol; 2012; 5(8):754-61. PubMed ID: 23071857
[TBL] [Abstract][Full Text] [Related]
9. Epithelial mesenchymal transition correlates with CD24+CD44+ and CD133+ cells in pancreatic cancer.
Zhang Y; Wei J; Wang H; Xue X; An Y; Tang D; Yuan Z; Wang F; Wu J; Zhang J; Miao Y
Oncol Rep; 2012 May; 27(5):1599-605. PubMed ID: 22322379
[TBL] [Abstract][Full Text] [Related]
10. Expression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis.
Durko L; Wlodarski W; Stasikowska-Kanicka O; Wagrowska-Danilewicz M; Danilewicz M; Hogendorf P; Strzelczyk J; Malecka-Panas E
Dis Markers; 2017; 2017():3276806. PubMed ID: 28659655
[TBL] [Abstract][Full Text] [Related]
11. Quantum dots affect expression of CD133 surface antigen in melanoma cells.
Steponkiene S; Kavaliauskiene S; Purviniene R; Rotomskis R; Juzenas P
Int J Nanomedicine; 2011; 6():2437-44. PubMed ID: 22072879
[TBL] [Abstract][Full Text] [Related]
12. ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma.
Kim MP; Fleming JB; Wang H; Abbruzzese JL; Choi W; Kopetz S; McConkey DJ; Evans DB; Gallick GE
PLoS One; 2011; 6(6):e20636. PubMed ID: 21695188
[TBL] [Abstract][Full Text] [Related]
13. Latexin exhibits tumor-suppressor potential in pancreatic ductal adenocarcinoma.
Xue Z; Zhou Y; Wang C; Zheng J; Zhang P; Zhou L; Wu L; Shan Y; Ye M; He Y; Cai Z
Oncol Rep; 2016 Jan; 35(1):50-8. PubMed ID: 26530530
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical detection of cancer stem cell related markers CD44 and CD133 in metastatic colorectal cancer patients.
Pitule P; Cedikova M; Daum O; Vojtisek J; Vycital O; Hosek P; Treska V; Hes O; Kralickova M; Liska V
Biomed Res Int; 2014; 2014():432139. PubMed ID: 24864242
[TBL] [Abstract][Full Text] [Related]
15. Circulating Tumor Cells Expressing Markers of Tumor-Initiating Cells Predict Poor Survival and Cancer Recurrence in Patients with Pancreatic Ductal Adenocarcinoma.
Poruk KE; Blackford AL; Weiss MJ; Cameron JL; He J; Goggins M; Rasheed ZA; Wolfgang CL; Wood LD
Clin Cancer Res; 2017 Jun; 23(11):2681-2690. PubMed ID: 27789528
[No Abstract] [Full Text] [Related]
16. Ezrin protein overexpression predicts the poor prognosis of pancreatic ductal adenocarcinomas.
Piao J; Liu S; Xu Y; Wang C; Lin Z; Qin Y; Liu S
Exp Mol Pathol; 2015 Feb; 98(1):1-6. PubMed ID: 25445504
[TBL] [Abstract][Full Text] [Related]
17. Deciphering the cellular source of tumor relapse identifies CD44 as a major therapeutic target in pancreatic adenocarcinoma.
Molejon MI; Tellechea JI; Loncle C; Gayet O; Gilabert M; Duconseil P; Lopez-Millan MB; Moutardier V; Gasmi M; Garcia S; Turrini O; Ouaissi M; Poizat F; Dusetti N; Iovanna J
Oncotarget; 2015 Apr; 6(10):7408-23. PubMed ID: 25797268
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer.
Wang C; Xie J; Guo J; Manning HC; Gore JC; Guo N
Oncol Rep; 2012 Oct; 28(4):1301-8. PubMed ID: 22895640
[TBL] [Abstract][Full Text] [Related]
19. Detection of tumor stem cell markers in pancreatic carcinoma cell lines.
Olempska M; Eisenach PA; Ammerpohl O; Ungefroren H; Fandrich F; Kalthoff H
Hepatobiliary Pancreat Dis Int; 2007 Feb; 6(1):92-7. PubMed ID: 17287174
[TBL] [Abstract][Full Text] [Related]
20. CD133+ CD44+ subgroups may be human small intestinal stem cells.
Hou NY; Yang K; Chen T; Chen XZ; Zhang B; Mo XM; Hu JK
Mol Biol Rep; 2011 Feb; 38(2):997-1004. PubMed ID: 20526812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
